| Q38503202 | A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors |
| Q89949443 | A Flexible Workflow for Automated Bioluminescent Kinase Selectivity Profiling |
| Q41811693 | A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies |
| Q89686626 | A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis |
| Q37063651 | A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects |
| Q58202794 | An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease |
| Q92133908 | Analog-sensitive cell line identifies cellular substrates of CDK9 |
| Q49315568 | Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
| Q42195551 | Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks. |
| Q90395495 | Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-N-(2-aryl-1H-benzo[d]imidazo-5-yl)isoxazole-4-carboxamide analogues as selective FLT3 inhibitors |
| Q35674207 | Covalent-Allosteric Kinase Inhibitors. |
| Q42697768 | Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. |
| Q53776575 | Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death. |
| Q28554596 | Decoding the Interactions Regulating the Active State Mechanics of Eukaryotic Protein Kinases |
| Q48009325 | Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors. |
| Q35804400 | Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis |
| Q49966216 | Design, Synthesis and Preliminary Biological Evaluation of Novel Benzyl Sulfoxide 2-Indolinone Derivatives as Anticancer Agents. |
| Q33859476 | Determining Cysteines Available for Covalent Inhibition Across the Human Kinome |
| Q38707609 | Diverse Molecular Targets for Chalcones with Varied Bioactivities |
| Q92566519 | Druggable exosites of the human kino-pocketome |
| Q37204806 | Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts |
| Q37622786 | From the research laboratory to the database: the Caenorhabditis elegans kinome in UniProtKB |
| Q38749038 | Gastric cancer management: Kinases as a target therapy |
| Q39020753 | HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma. |
| Q38366266 | Hedgehog inhibitors: a patent review (2013 - present). |
| Q28081001 | Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases |
| Q33796957 | Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells |
| Q38814898 | Innovative computer-aided methods for the discovery of new kinase ligands |
| Q33811883 | Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome |
| Q38780465 | Integration of phytochemicals and phytotherapy into cancer precision medicine. |
| Q47439880 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases |
| Q48556502 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q38760031 | Kinase targets in CNS drug discovery. |
| Q60046417 | Kinase-Based Taming of Brain Microglia Toward Disease-Modifying Therapy |
| Q38604840 | Lighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics. |
| Q38472067 | Masitinib for the treatment of mild to moderate Alzheimer's disease |
| Q34906440 | Mitochondrial DNA somatic mutation in cancer |
| Q38739347 | Multitarget Drugs: an Epigenetic Epiphany. |
| Q91941572 | Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q43189953 | Phosphorylation, Signaling, and Cancer: Targets and Targeting |
| Q38802154 | Principles of Kinase Inhibitor Therapy for Solid Tumors. |
| Q51021213 | Production of Protein Kinases in E. coli. |
| Q60307896 | Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states |
| Q38495042 | Re-positioning protein-kinase inhibitors against schistosomiasis |
| Q47672478 | Recent advances in phosphoproteomics and application to neurological diseases |
| Q90274971 | Reversal of ABCB1-related multidrug resistance by ERK5-IN-1 |
| Q33777835 | Screening and identification of novel biologically active natural compounds |
| Q35992573 | Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model |
| Q61810277 | Smp38 MAP Kinase Regulation in : Roles in Survival, Oviposition, and Protection Against Oxidative Stress |
| Q91943837 | Specificity, versatility, and control of TGF-β family signaling |
| Q89207719 | Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs |
| Q47218042 | Strategies to target the Hedgehog signaling pathway for cancer therapy. |
| Q64275602 | Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt |
| Q58713486 | Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B |
| Q38910326 | Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. |
| Q28553277 | The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective |
| Q51800912 | The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment. |
| Q36321573 | The Snf1-activating kinase Sak1 is a key regulator of metabolic adaptation and in vivo fitness of Candida albicans |
| Q90613923 | The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications |
| Q45070681 | Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer |
| Q38930166 | Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas |
| Q49888021 | Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. |
| Q36088545 | UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib |
| Q35921419 | cJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation |